Fig. 6: T cells are required for the recruitment of β-glucan-trained neutrophils to the lung tissue.
From: β-Glucan reprograms neutrophils to promote disease tolerance against influenza A virus
a–c, Rag1−/− mice (a) were infected with IAV lethal dose (b) and sublethal dose (c) at day 7 post-β-glucan treatment to assess survival (n = 10). d, C57BL/6 (WT and Rag1−/−) mice were treated with β-glucan. e–h, Expansion of LKSs (e), MPPs (f), GMPs (g) and GPs (h) assessed in the BM on day 4 post-β-glucan treatment (n = 5). i,j, Total cell counts of neutrophils in BM (i) and lungs (j) on day 4 post-β-glucan treatment (n = 8). k, C57BL/6 (WT and Rag1−/−) mice infected with IAV infection on day 7 post-β-glucan. l, Total cell counts of neutrophils in the lungs at day 6 post-IAV infection (n = 4). m, Mice were treated with β-glucan and after 4 d lungs subjected to MACSima imaging. n, Quantification of corresponding pulmonary immune cells from MACSima imaging (n = 4). o, Quantification of RORγt CD4+ T cells after β-glucan treatment (n = 5). p, Intravascular staining of RORγtGFP/GFP or RORγtWT/GFP at day 4 post β-glucan treatment. q,r, Total cell counts of neutrophils in the lung vasculature (q) and parenchyma (r) (n = 4). s, RORγtGFP/GFP or RORγtWT/GFP mice infected with IAV (lethal dose) at day 7 post-β-glucan treatment to assess survival. Data are represented as mean ± s.e.m. Data were analyzed using two-tailed, unpaired Student’s t-test (n), one-way ANOVA followed by Tukey’s multiple-comparison test (o) and two-way ANOVA followed by Šidák’s multiple-comparison tests (e–j, l, q and r). Survival was monitored by a log(rank) test (b, c and s). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. NS, not significant. Illustrations in a, d, k and p created using BioRender.com.
